ImmunityBio, Inc. - Common Stock (IBRX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- Piotroski F-Score 3/9 — signs of financial weakness
- ROE of 143.2% — good return on equity
- Revenue growing at 668% annually
ImmunityBio, Inc. - Common Stock (IBRX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $8.9 billion . Key value metrics: Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ImmunityBio, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, IBRX shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and strong return on equity of 143.2% (sector average: -20.6%).
StockPik's composite Value Score for IBRX is 40/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
IBRX reports a high gross margin of 99.5% (sector average: 40.1%) and a negative operating margin of -219.1%.
IBRX shows revenue growing at 668% year-over-year, with earnings growing at 15%.